Microcap Ledger Cumberland Pharmaceuticals Inc $CPIX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Nashville,, TN
- Fiscal year end
- December 31
- Shares outstanding
- 14,983,107 [10-Q 2026-08-07]
What the company doesAI summary of filing
Cumberland Pharmaceuticals Inc. is a revenue-generating specialty pharmaceutical company that acquires, develops, and commercializes branded prescription drugs focused on hospital acute care, gastroenterology, and oncology markets. The company sells seven FDA-approved marketed products through dedicated hospital, field, and oncology sales divisions in the United States, generates revenue from wholesale pharmaceutical distributors, and has established international partnerships to commercialize its medicines in other countries. Cumberland also operates a clinical-stage pipeline with ifetroban undergoing Phase II trials for rare diseases including Duchenne muscular dystrophy-associated cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis. [10-K 2026-03-09]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $330.3K | −$7.57M | $555.8K | $3.86M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $44.52M | −$2.84M | $4.93M | $11.44M | [10-K 2026-03-09] |
| FY ended Dec 2024 | $37.87M | −$6.48M | −$612.2K | $17.96M | [10-K 2026-03-09] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 14,042,304 | [10-Q 2024-11-08] |
| 2025-03-04 | 13,968,394 | [10-K 2025-03-07] |
| 2025-05-06 | 14,961,137 | [10-Q 2025-05-09] |
| 2025-08-05 | 14,959,937 | [10-Q 2025-08-08] |
| 2025-11-05 | 14,956,627 | [10-Q 2025-11-07] |
| 2026-03-04 | 14,956,627 | [10-K 2026-03-09] |
| 2026-05-05 | 14,983,107 | [10-Q 2026-05-08] |
| 2026-08-05 | 14,983,107 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2023-12-14; declared effective 2023-12-26 [S-3 2023-12-14]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-18 | Brown Martin S Jr | grant | 1,800 | $2.80 | [4 2026-03-20] |
| 2026-03-18 | Galante Joseph C | grant | 1,800 | $2.80 | [4 2026-03-20] |
| 2026-03-18 | Jones James | grant | 1,800 | $2.80 | [4 2026-03-20] |
| 2026-03-18 | Krogulski Kenneth | grant | 1,800 | $2.80 | [4 2026-03-20] |
| 2026-03-18 | Krogulski Kenneth | grant | 4,000 | $2.80 | [4 2026-03-20] |
| 2026-03-18 | Young Caroline | grant | 1,800 | $2.80 | [4 2026-03-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-11 | 8-K | Shareholder vote results |
| 2026-08-28 | 8-K | Regulation FD disclosure |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Results of operations |
| 2026-07-13 | 8-K | Other events |
| 2026-07-01 | 8-K | Material agreement entered; Material agreement terminated; Acquisition or disposition completed |
| 2026-06-25 | 8-K | Shareholder vote results |
| 2026-05-08 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Results of operations |
| 2026-04-24 | 8-K | Shareholder vote results |
| 2026-04-23 | 8-K | Material agreement entered; Regulation FD disclosure; Other events |
| 2026-03-09 | DEF 14A | Proxy statement |
Alerts for $CPIX
Email me when Cumberland Pharmaceuticals Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.